Welcome to our dedicated page for Fluttr Entrtnmnt SEC filings (Ticker: FLUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Flutter Entertainment’s SEC documents can span hundreds of pages, covering everything from wagering margins in the U.S. FanDuel segment to licence renewals in Australia. Finding where the 10-K explains responsible-gaming provisions or which Form 4 shows an executive exercising performance-linked options often requires deep regulatory knowledge.
Stock Titan solves that problem. Our AI-powered summaries translate complex disclosures into plain language and flag the details most equity analysts track: segment EBITDA shifts, live-betting hold percentages, and material licence awards. Real-time alerts mean you see each Flutter Entertainment insider trading Form 4 transactions filing the moment it hits EDGAR, without refreshing pages.
Use the navigation below to jump straight to the information you need:
- 10-K annual report – Flutter Entertainment annual report 10-K simplified to highlight tax rates, customer acquisition costs, and risk factors.
- 10-Q quarterly updates – access every Flutter Entertainment quarterly earnings report 10-Q filing with margin analysis and U.S. share metrics.
- 8-K event reports – Flutter Entertainment 8-K material events explained for licence wins, M&A announcements and regulatory changes.
- DEF 14A proxy – review the Flutter Entertainment proxy statement executive compensation section without scrolling through tables.
- Form 4 dashboard – track Flutter Entertainment Form 4 insider transactions real-time and spot buying or selling trends.
Whether you’re comparing revenue mix, analysing Flutter Entertainment earnings report filing analysis, or simply understanding Flutter Entertainment SEC documents with AI, every filing is indexed, searchable and paired with concise guidance. Stay informed, act faster, and rely on one source for complete regulatory insight.
OneMedNet Corporation (Nasdaq: ONMD) filed an 8-K detailing a series of equity and debt restructuring transactions completed between 17-20 June 2025.
- $2.5 million private placement: 3,390,923 common shares and pre-funded warrants for 2,561,457 shares were sold to an accredited investor at $0.42 per share. Warrants are immediately exercisable at $0.0001. A voting agreement binds the investor to Board recommendations. The company will register the resale shares via an S-1 amendment.
- Insider subscriptions: Director Dr. Thomas Kosasa invested $0.5 million for 1,190,476 shares; CMO/Chairman Dr. Jeffrey Yu invested $0.7 million for 1,666,666 shares, both at $0.42.
- Loan conversions: • $3.3 million of shareholder loans (Kosasa $2.0 m, Yu $1.3 m) converted into 4,693,299 shares at $0.71.
• Kosasa elected to convert an additional $1.6 million of convertible loans into 2,123,424 shares at $0.7535.
• Holders of $1.66 million PIPE Notes converted into 1,453,174 shares at $1.14. - Liability settlement: The company settled ~$4.34 million of trade payables, including $2.76 million deferred underwriter fees. It also redeemed the remaining $250,000 balance of a Yorkville promissory note for cash.
In aggregate, ONMD raised $3.7 million in new equity capital and eliminated or converted approximately $11 million of current liabilities—representing a 60 % reduction relative to 31 March 2025. However, the transactions add roughly 17 million new or issuable shares, materially increasing outstanding share count and potential dilution. Net proceeds are earmarked for general corporate purposes and working capital.
USANA Health Sciences, Inc. (USNA) filed an 8-K to disclose that on 27 June 2025 it signed a Third Amended and Restated Credit Agreement with Bank of America and a syndicate of lenders.
- Size & Flexibility: The agreement establishes a $75 million secured revolving credit facility that can be expanded by up to an additional $200 million at the company’s option, providing significant liquidity headroom.
- Collateral: Borrowings are secured by a pledge of subsidiary capital stock under a companion Security and Pledge Agreement.
- Pricing: Loans accrue interest at variable rates tied to Term SOFR, Daily Simple SOFR, or the Base Rate, each plus an applicable margin defined in the agreement.
- Key Covenants: (1) Minimum consolidated EBITDA of $80 million through Q2-26, rising to $100 million thereafter. (2) Maximum consolidated funded-debt-to-EBITDA ratio of 2.0× every quarter. These metrics are tested quarterly beginning Q2-25.
- Capital Return Flexibility: The credit agreement does not restrict cash dividends or share repurchases, preserving USANA’s shareholder-return policy.
- Events of Default: Standard provisions allow lenders to accelerate all obligations and terminate commitments upon payment, covenant, or insolvency breaches.
The facility enhances USANA’s liquidity profile, replaces prior arrangements on updated SOFR-linked terms, and obligates the company to maintain disciplined leverage and profitability levels.